Arvinas (ARVN) News Today $9.75 +0.45 (+4.84%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$9.58 -0.17 (-1.75%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Arvinas price target raised to $16 from $14 at Piper SandlerOctober 7 at 6:27 PM | msn.comArvinas price target raised to $12 from $10 at BofAOctober 7 at 1:23 PM | msn.comArvinas presents data from two Phase 1 trials for ARV-102October 6 at 2:54 AM | msn.comArvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement ...October 5, 2025 | markets.businessinsider.comArvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®October 5, 2025 | globenewswire.comArvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®October 1, 2025 | markets.businessinsider.comArvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®October 1, 2025 | globenewswire.comBrokerages Set Arvinas, Inc. (NASDAQ:ARVN) Price Target at $16.18October 1, 2025 | americanbankingnews.comArvinas, Inc. $ARVN Shares Sold by Assenagon Asset Management S.A.September 29, 2025 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 28, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Trading 4.9% Higher - What's Next?September 26, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Director Briggs Morrison Purchases 30,000 SharesSeptember 25, 2025 | insidertrades.comPalumbo Wealth Management LLC Acquires Shares of 66,858 Arvinas, Inc. $ARVNSeptember 25, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Director Briggs Morrison Buys 30,000 SharesSeptember 24, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Downgraded by Bank of America to "Neutral"September 24, 2025 | marketbeat.comClear Harbor Asset Management LLC Acquires New Holdings in Arvinas, Inc. $ARVNSeptember 24, 2025 | marketbeat.comArvinas downgraded to Neutral from Buy at BofASeptember 24, 2025 | msn.comGoldman Sachs Group Inc. Sells 74,982 Shares of Arvinas, Inc. $ARVNSeptember 20, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Board of Directors Initiates Stock Repurchase PlanSeptember 19, 2025 | marketbeat.comArvinas price target lowered to $10 from $16 at BTIGSeptember 19, 2025 | msn.comArvinas (NASDAQ:ARVN) Earns "Neutral" Rating from WedbushSeptember 19, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Price Target Lowered to $10.00 at BTIG ResearchSeptember 19, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Given New $14.00 Price Target at StephensSeptember 19, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Upgraded to Strong-Buy at BarclaysSeptember 19, 2025 | marketbeat.comArvinas price target lowered to $14 from $16 at StephensSeptember 18, 2025 | msn.comBarclays Reiterates Overweight Rating for Arvinas (NASDAQ:ARVN)September 18, 2025 | marketbeat.comArvinas, Pfizer to out-license commercialization rights to vepdegestrantSeptember 18, 2025 | msn.comAcadian Asset Management LLC Buys New Position in Arvinas, Inc. $ARVNSeptember 18, 2025 | marketbeat.comArvinas announces $100M share repurchase programSeptember 18, 2025 | msn.comArvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third partySeptember 17, 2025 | reuters.comArvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value CreationSeptember 17, 2025 | globenewswire.comArvinas initiated with an Overweight at BarclaysSeptember 17, 2025 | msn.comArvinas assumed with an Overweight at BarclaysSeptember 17, 2025 | msn.comArvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 9, 2025 | seekingalpha.comPhilosophy Capital Management LLC Makes New $6.99 Million Investment in Arvinas, Inc. $ARVNSeptember 8, 2025 | marketbeat.comEdmond DE Rothschild Holding S.A. Buys 50,000 Shares of Arvinas, Inc. $ARVNSeptember 8, 2025 | marketbeat.com1,800,000 Shares in Arvinas, Inc. $ARVN Purchased by Alyeska Investment Group L.P.September 7, 2025 | marketbeat.comInvesco Ltd. Boosts Stock Position in Arvinas, Inc. $ARVNSeptember 7, 2025 | marketbeat.com313,354 Shares in Arvinas, Inc. $ARVN Acquired by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comGraham Capital Management L.P. Grows Stock Holdings in Arvinas, Inc. $ARVNSeptember 4, 2025 | marketbeat.comRussell Investments Group Ltd. Increases Stock Position in Arvinas, Inc. $ARVNSeptember 3, 2025 | marketbeat.comNuveen LLC Invests $1.17 Million in Arvinas, Inc. $ARVNSeptember 3, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Cuts Stock Position in Arvinas, Inc. $ARVNSeptember 1, 2025 | marketbeat.comArvinas to Participate in Upcoming Investor ConferencesAugust 29, 2025 | globenewswire.comT. Rowe Price Investment Management Inc. Has $3.85 Million Stock Holdings in Arvinas, Inc. $ARVNAugust 27, 2025 | marketbeat.comVanguard Group Inc. Buys 1,299,639 Shares of Arvinas, Inc. $ARVNAugust 26, 2025 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX TopcoAugust 24, 2025 | finance.yahoo.comArvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX TopcoAugust 23, 2025 | insidermonkey.comAlgert Global LLC Has $3.26 Million Position in Arvinas, Inc. $ARVNAugust 22, 2025 | marketbeat.comArvinas FY2025 EPS Estimate Lowered by Cantor FitzgeraldAugust 12, 2025 | marketbeat.com Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARVN Media Mentions By Week ARVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARVN News Sentiment▼-0.080.63▲Average Medical News Sentiment ARVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARVN Articles This Week▼67▲ARVN Articles Average Week Get the Latest News and Ratings for ARVN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Arvinas and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies OGN News Today BEAM News Today ALVO News Today CPRX News Today MLYS News Today BLTE News Today GLPG News Today CDTX News Today IDYA News Today IRON News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARVN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
